PMID- 21946246
OWN - NLM
STAT- MEDLINE
DCOM- 20111205
LR  - 20220318
IS  - 1531-703X (Electronic)
IS  - 1040-8746 (Print)
IS  - 1040-8746 (Linking)
VI  - 23
IP  - 6
DP  - 2011 Nov
TI  - Current status of allogeneic transplantation for aggressive non-Hodgkin lymphoma.
PG  - 681-91
LID - 10.1097/CCO.0b013e32834bb88e [doi]
AB  - PURPOSE OF REVIEW: To provide a succinct update on the role of allogeneic stem 
      cell transplantation (allo-SCT) in the management of patients with aggressive 
      lymphomas. To clarify the indications for allogeneic transplantation vis-a-vis 
      autologous transplant and to discuss the rationale and potential benefits of 
      reduced intensity conditioning (RIC), nonmyeloablative (NMA) transplant, T-cell 
      depletion and variations in graft vs. host disease (GVHD) prophylaxis. RECENT 
      FINDINGS: Considerable effort has been spent in developing transplant regimens 
      with reduced toxicity and reduced GVHD. The role of allogeneic transplantation 
      has also been redefined in light of advances in lymphoma classification, 
      diagnostic methods, particularly PET scan and advances in transplant technology. 
      Haplo and umbilical cord blood SCT allow identification of a donor for nearly all 
      patients. SUMMARY: In diffuse large B-cell lymphoma, the outcome of allo-SCT 
      depends on patient characteristics and chemosensitivity. It is useful after 
      failure of auto-SCT and in partial responses to salvage therapy. Allo-SCT may be 
      the treatment of choice for advanced T-cell and natural killer cell lymphoma and 
      for adult T-cell leukemia-lymphoma. Prophylactic or preemptive donor lymphocyte 
      infusion may be useful, but requires controlled studies. RIC and NMA conditioning 
      have reduced early toxicity but are associated with increased risk for disease 
      recurrence. Promising data have been reported from a novel conditioning regimen 
      combining NMA with ibritumomab tiuxetan. T-cell depletion reduces chronic GVHD 
      but has some increase in rate of recurrence. Rapamycin may be associated with 
      reduction in risk for disease recurrence.
FAU - van Besien, Koen
AU  - van Besien K
AD  - Stem Cell Transplant Program, University of Chicago, Chicago, Illinois, USA.
LA  - eng
GR  - K24 CA116471/CA/NCI NIH HHS/United States
GR  - 5K24CA116471-05/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Review
PL  - United States
TA  - Curr Opin Oncol
JT  - Current opinion in oncology
JID - 9007265
SB  - IM
MH  - Graft vs Tumor Effect
MH  - Humans
MH  - Lymphoma, Large B-Cell, Diffuse/immunology/surgery
MH  - Lymphoma, Non-Hodgkin/immunology/*surgery
MH  - Stem Cell Transplantation/*methods
MH  - Transplantation, Homologous
PMC - PMC4811671
MID - NIHMS348484
EDAT- 2011/09/29 06:00
MHDA- 2011/12/13 00:00
PMCR- 2016/03/29
CRDT- 2011/09/28 06:00
PHST- 2011/09/28 06:00 [entrez]
PHST- 2011/09/29 06:00 [pubmed]
PHST- 2011/12/13 00:00 [medline]
PHST- 2016/03/29 00:00 [pmc-release]
AID - 10.1097/CCO.0b013e32834bb88e [doi]
PST - ppublish
SO  - Curr Opin Oncol. 2011 Nov;23(6):681-91. doi: 10.1097/CCO.0b013e32834bb88e.